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Abstract
Background: Paraneoplastic neurological syndromes (PNS) are rare disorders associated with malignant tumours,
which are triggered by autoimmune reactions. Paraneoplastic cerebellar degeneration (PCD) is the PNS type most
commonly associated with ovarian and breast cancer. Two bladder cancers manifesting in PCD were previously
reported. However, the cancers in these cases had poor outcomes.
Case presentation: Here, we present a 68-year old man with history of high-grade papillary urothelial carcinoma of
the bladder. The patient suffered from persistent cerebellar ataxia accompanied by bladder cancer recurrence five
months after transurethral resection of the bladder tumour (TURBt). Laboratory screening for the specific antibodies
of paraneoplastic neurological syndromes revealed no positive results. Symptoms were not remitted after a
7-day-course of high-dose glucocorticoid therapy. To our surprise, the patient recovered fully after laparoscopic
radical cystectomy. Postoperative pathology revealed that surgical specimens were urothelial carcinoma in situ (CIS)
and squamous cell carcinoma of the bladder. The patient remained asymptomatic and there was no evidence of
recurrence after the followup period of 11 months.
Conclusion: To our knowledge, this is the third report of PCD in a patient with bladder cancer. This case showed
that tumour resection cured the PCD. To assist clinical evaluation and management, literature regarding basic PNS
characteristics and bladder cancers was reviewed.
Keywords: Paraneoplastic cerebellar degeneration, Bladder cancer, High grade urothelial, Carcinoma, Squamous
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Background
The bladder cancer is the 11th most common site of
cancer diagnosis and the 14th leading cause of cancer-
related deaths in the world [1]. The 2004 WHO/ISUP
system classifies papillary urothelial neoplasms into four
types: papilloma, papillary urothelial neoplasm of low
malignant potential, low-grade papillary urothelial car-
cinoma, and high-grade papillary urothelial carcinoma
[2]. The high-grade papillary urothelial carcinoma was
associated with the high recurrence rate. The main clin-
ical treatment for non-muscle-invasive bladder cancer is
transurethral resection of Ta and T1 bladder tumours
[3]. However, carcinoma in situ (CIS) is a high-grade,
flat, non-invasive urothelial form. This carcinoma is
often multifocal and progresses to muscle-invasive dis-
ease. Therefore, endoscopic procedures alone are insuf-
ficient for CIS treatment. Either intravesical bacillus
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Calmette-Guérin (BCG) instillations or radical cystecto-
mies (RC) are applied [4, 5]. Several studies have revealed
excellent outcomes after immediate RC for CIS [6].
Paraneoplastic neurological syndromes (PNS) are rare
disorders associated with malignant tumours that are not
directly caused by tumour invasion and metastasis. The
autoimmune response is elicited by the ectopic expression
of neural antigens in neoplastic tissues, which eventually
attack the nervous system of PNS patients [7]. PNS inci-
dence is estimated to be 0.5–1 %, varying by cancer type
[8, 9]. Paraneoplastic cerebellar degeneration (PCD) is the
type of PNS most commonly associated with ovarian and
breast cancer [9]. PCD is characterized by subacute cere-
bellar ataxia within 12 weeks and subsequent cerebellar
atrophy [10]. Bladder cancers presenting with PCD have
rarely been reported. Greenlee JE [11] and Tetsuka S [12]
reported PCD and its causal antibody in bladder cancer
patients. Here, we discuss a patient with urothelial CIS of
the bladder who suffered from PCD. Unlike two previous
cases, we found no specific antibody causing PCD. Litera-
ture concerning unusual cases are reviewed.
Case presentation
A 68-year-old man was admitted to the Qilu Hospital
of Shandong University on November 17, 2014 for
urinary irritation, dysuria and haematuria. The patient’s
condition was good, and weight loss, night sweats and
recent fever did not present. Urinalysis showed red and
white blood cell counts of 61.4/μL and 313.8/μL, re-
spectively. Cystoscopy showed scattered cauliflower-like
neoplasms located at 11°-1° of the narrow bladder neck,
with a maximum diameter of 1.5 cm. A biopsy was then
conducted and the pathological examination revealed
that the neoplasms were high-grade papillary urothelial
carcinoma of the bladder. CT scanning showed a thick-
ened anterior bladder wall, without enlarged pelvic
lymph nodes. Transurethral resection of the bladder
tumour (TURBt) was conducted after a definitive diag-
nosis was made. Several villous tumours were found on
the neck of the bladder during the operation. The post-
operative pathological examination showed that the
surgical specimens were high-grade papillary urothelial
carcinoma accompanied by differentiated squamous cell
carcinoma. This carcinoma also involved the prostate.
Haematuria and dysuria symptoms disappeared after
TURBt. Therefore, the patient’s family refused further
treatment and the patient was discharged.
The patient was referred to our hospital again on
March 27, 2015 because of vomiting, progressive gait
imbalance and Haematuria for the previous five days.
Neurological examinations revealed ataxic gait and bilat-
eral coarse nystagmus. Slight dysmetria was confirmed by
finger-to-nose and heel-knee-shin testing. Haematuria led
to the performance of a urinalysis showing red and white
blood cell counts of 554/μL and 6748/μL, respectively.
Further cystoscopy revealed that bladder mucosa located
at 11°-1° of the bladder neck suffered hyperaemia, edema,
and erosion of the asperous surface. The biopsy showed a
high-grade papillary urothelial carcinoma and squamous
differentiation.
Further laboratory and radiographic evaluations were
conducted to clarify the relationship between bladder
cancer recurrence and emerging cerebellar ataxia. A
brain MRI was performed to exclude brain metastases
from bladder cancer (Fig. 1 c, d). The MRI revealed no
obvious morphological change of the cerebellum (Fig. 1
a, b). The abdominal and pelvic CT scans revealed that
the bladder wall was thickened, especially at the neck
(Fig. 2). The above radiographic findings suggest little
possibility exists that nervous symptoms were triggered
by brain metastases from bladder cancer.
Further laboratory examinations were conducted to
validate the cause of neurological symptoms. Nine com-
mon types of paraneoplastic antibodies were all negative
in the serum and cerebrospinal fluid (CSF). Details of
the paraneoplastic antibodies are shown in Table 1. The
CSF examination revealed an elevated level of protein
(58.6 mg/dl, normal: 15–45 mg/dl), IgG (39.5 mg/L,
normal < 34 mg/L), and albumin (391 mg/L, normal <
350 mg/L). Pandy's test of CSF was positive, while CSF
cell counts were normal. Tumour markers showed that
squamous cell cancer antigen (SCC) and non-small cell
lung cancer antigen (CYFRA21-1) serum concentra-
tions were elevated (SCC: 6 ng/ml, normal: 0.1–0.3 ng/
ml; CYFRA21-1: 3.5 ng/ml, normal < 1.5 ng/ml). The
thyroglobulin serum concentration was low (<0.04 ng/ml,
normal: 1.4-78 ng/ml). The examination of rheumatic
antigens revealed no positive results. The electroenceph-
alogram revealed no epileptogenic activity.
Based on these findings, we suspected that the patient
suffered from PCD. The patient initially received a 5-day
course of methylprednisolone (500 mg intravenously daily)
without significant clinical improvement. Considering the
first postoperative pathological examination revealed the
bladder cancer involved the prostate and recurred, the pa-
tient underwent laparoscopic radical cystectomy (LRC).
The postoperative pathological examination revealed that
the surgically removed bladder was urothelial CIS and
well-differentiated squamous cell carcinoma (Fig. 3). This
finding was in accordance with the changes in serum SCC
and CYFRA21-1. The squamous cell carcinoma was dis-
persed in the bladder mucosa (Fig. 3a) and accounted for
approximately 5 % of all carcinomas. Neurological symp-
toms disappeared, and basic daily living activities were
obviously improved, according to Barthel score (Table 2),
after LRC. The patient remained asymptomatic and there
was no evidence of recurrence after the followup period of
11 months.
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Discussion
PNS was initially defined as the presence of cancer and
the exclusion of other known causes of the neurological
symptoms. Examples of such causes include metastasis,
coagulopathy, infections, metabolic or nutritional distur-
bances, and treatment-induced neurotoxicity [10, 13].
The exact pathogenesis of most PNS is unknown. How-
ever, neuronal antigens expressed by cancers could acti-
vate the immune system. Moreover, many antineuronal
antibodies generated by the activated immune system
attack the nervous system [7]. Antineuronal antibodies
can affect different nervous system regions, and multiple
clinical manifestations can present in PNS. When the
cerebellum is affected, the rapid development of severe
cerebellar ataxia is caused by extensive Purkinje neurons
loss, defined as PCD.
According to the PNS Euronetwork recommended
diagnostic framework in 2004 [13], the following criteria
are required to define PCD: (1) severe pancerebellar syn-
drome developing in less than 12 weeks; (2) no radio-
graphic evidence of cerebellar atrophy other than that
expected by the patient’s age; and (3) the significant
interference of symptoms caused by PCD with basic
activities of daily living. Neurological syndromes devel-
oped in five days and the MR examnation excluded cere-
bellar atrophy in the present case. The Barthel activities
of daily living Index was 35 after the onset of the disease,
indicating a severe effect. All the characteristics in the
Fig. 1 Magnetic resonance imaging (MRI) of the brain. a and b, the T2WI sagittal scan showed no obvious morphological change of the cerebellum;
c and d, the enhanced-scanning MRI revealed no sign of brain metastases from bladder cancer
Fig. 2 Computed tomography (CT) of the abdomen and pelvis. A, the bladder wall was thickened; B, the neck of bladder was thicker than the
bladder wall
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present case met PCD diagnostic criteria. Other possible
reasons for neurological syndromes were excluded. The
neurological syndromes associated with bladder cancer
could be clinically diagnosed as PCD.
PNS is commonly associated with ovarian cancer,
breast cancer, SCLC, or Hodgkin’s disease. Few reports
have associated PNS with bladder cancer. We retro-
spectively reviewed English literature regarding PNS
and bladder cancers. We used PubMed, Medscape and
EMBASE to search for studies on this topic, yielding
eight articles. Only two reported a relationship between
PCD and bladder cancer. Therefore, this study is the third
to describe the relationship between PCD and bladder
cancer. Clinical and pathological features were summa-
rized according to previous reports and the present case
(Table 3).
The male to female ratio of 2 to 1 in the nine related
cases is different from the bladder cancer incidence rate.
The worldwide incidence rate is believed to be 8.9/
100,000 and 2.2/100,000 for men and women, respect-
ively. Therefore, the male to female ratio is more than 4
to 1 [1]. Sean et al. reported that the female to male
ratio of 34 PNS patients seropositive for anti-Ri was 2 to
1 [14]. British data showed a striking female preponder-
ance of PNS, with a female to male ratio of 2.3 to 1 [15].
Therefore, the female patients with bladder cancer may
be predisposed to PNS. This finding is the same as for
PNS caused by other cancers.
PNS is caused by high-grade muscle-invasive bladder
cancer in most cases. Blood supplies of the muscle-
invasive bladder cancer are richer, facilitating the circu-
lation of neuronal antigens expressed by high-grade can-
cers. In the present case, the patient with the urothelial
CIS and squamous cell carcinoma of the bladder suf-
fered from PCD. Matsumoto L. reported that CIS of the
testis triggered severe hypokinesis as a paraneoplastic
manifestation and detection of anti-Ma2 antibodies [16].
In this case, the bladder cancers comprised high-grade
urothelial carcinoma and well-differentiated squamous cell
carcinoma. However, methods of verifying which type of
carcinoma causing PCD are limited. Gita reported that re-
current bladder cancers with squamous features caused
paraneoplastic encephalomyelitis [17]. Numerous reports
of other organs have also demonstrated that PNS was
caused by squamous cell carcinoma [18, 19]. Therefore,
Table 1 Examination Results of Paraneoplastic Antibodies












Fig. 3 HE staining of bladder cancer tissues. a, HE staining showed irregular squamous cell carcinoma dispersed in the bladder mucosa. b, HE
staining showed the urothelial CIS
Table 2 Barthel Index of Activities of Daily Living Before and
After LRC
Activities Independent Needs help Unable Before LRC After LRC
Feeding 10 5 0 5 10
Transfer 15 5 or 10 0 0 10
Grooming 5 0 / 0 5
Toilet use 10 5 0 5 10
Bathing 5 0 / 0 5
Dressing 10 5 0 5 10
Mobility 15 5 or 10 0 0 10
Stairs 10 5 0 0 5
Bowels 10 5 0 10 10
Bladder 10 5 0 10 10
Total Score 100 35 85
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Table 3 Clinical and Pathological Features in Nine Cases of Bladder Cancer with PNS
Case No. Author Year Age/Gender Stage Pathology Clinical syndromes Antibody Treatment Prognosis
1 Gita et al.[17] 2015 73/F Ma Poorly differentiated carcinoma with
squamous features
PEM Negtive Surgical resection and
immunosuppression
Partial improvement
2 Syuichi et al.[12] 2013 66/M N/A Urothelial carcinoma PCD Anti-CKB TURBT No improvement
3 Lukacs et al.[20] 2012 76/F pTa Urothelial carcinoma PEM and SSN Anti-Hu TURBT Partial improvement
4 Forte et al.[21] 2009 76/M pT2 High grade urothelial carcinoma Neuromyotonia Anti-
VGKC
Resectionofthetumour Complete improvement
5 Sean et al.[14] 2003 59/M N/A N/A POM Anti-Ri N/A N/A
6 Charles et al.[22] 2001 57/M pT3 High grade urothelial carcinoma POM Anti-Ri Radical cystectomy and
immunosuppression
Partial improvement






8 John et al.[11] 1999 64/F pT2 High grade urothelial carcinoma PCD Anti-Yo Partial resection of the
bladder
No improvement
9 Current report 2015 68/M pCIS High grade urothelial carcinoma and the
well-differentiated squamous cell
carcinoma
PCD Negtive Laparoscopic radical
cystectomy
Complete improvement
aA recurrent pelvis mass proven as urothelial carcinoma 22 years after radical cystectomy; PEM Paraneoplastic encephalomyelitis; PCD Paraneoplastic cerebellar degeneration; SSN Subacute sensory neuronopathy; POM











we believe the PNS is more likely to arise in patients
with high grade urothelial carcinoma with squamous
differentiation.
Onconeural antibodies are of vital importance in PNS
pathogenesis and diagnosis. However, only 60–70 % of
patients have detectable onconeural antibodies [10].
Onconeural antibodies were not detected in the present
case. Table 3 shows that the bladder cancer antibodies
inducing PNS are anti-Ri, anti-Hu, anti-Yo and anti-
VGKC. SCC and CYFRA21-1 serum concentrations
were increased. SCC and CYFRA21-1 are squamous cell
carcinoma markers and not paraneoplastic antibodies.
No relationship between the low serum thyroglobulin
level and PCD is believed to exist. The low serum thyro-
globulin level may be due to primary thyroid changes.
Early treatment of the related tumour is the best way
to promote neurological improvement. The therapeutic
effects of immune therapy were unsatisfactory in these
nine cases. The underlying bladder cancer received early
diagnosis and timely radical cystectomy. Therefore, in-
jury to the nervous systems was reversible, and PNS
disappeared in the present case. Thus, patients with
muscle-invasive bladder cancer or CIS of the bladder
that simultaneously suffered from PNS require timely
radical cystectomy to avoid irreversible injury to the
nervous system.
Conclusion
The patient in the present case suffering from PCD
attained a good prognosis. This prognosis was due to
early diagnosis and timely radical cystectomy. PNS has
an obvious female preponderance in patients with blad-
der cancers. PNS is more likely to arise in patients with
high grade urothelial carcinoma with squamous differ-
entiation. Therefore, timely radical cystectomy is neces-
sary to achieve a good prognosis.
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